IPSEN : Innovation for patient care

  • News
  • Our Products
  • Disease Areas
Our Products

Acromegaly

Increlex

Description

Increlex (mecasermin) is a recombinant DNA-derived human insulin-like growth factor-1 (IGF-1) produced in Escherichia coli.

Increlex is the first and only product licensed in Europe for the long term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency (IGFD).

Severe Primary IGFD is a complex condition where children's IGF-1 levels are low, despite the presence of normal or elevated Growth Hormone (GH) levels. Without adequate IGF-1 these children cannot achieve normal height.

Indications

For the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency (Primary IGFD).


Severe Primary IGFD is defined in the licence approval by several key factors:


  • Height standard deviation scores = -3.0 and
  • Basal IGF-1 levels below the 2.5th percentile for age and gender and
  • GH sufficiency.
  • Exclusion of the secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacological doses of anti-inflammatory steroids.

An IGF-1 generation test can be used to confirm diagnosis.



FULL PRESCRIBING INFORMATION

In compliance with the guidelines of the Irish Pharmaceutical Healthcare Association, the self-regulatory body of the pharmaceutical industry in Ireland, the full prescribing information for all of Ipsen's products in Ireland are available now on www.medicines.ie